Buford, Ga–Theragenics Corporation(R) (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it completed the acquisition of NeedleTech Products, Inc., on July 28, 2008. The agreement to acquire NeedleTech for $47.8 million was previously announced by Theragenics on July 16, 2008. (more…)

Durham, NC - Slate Pharmaceuticals, a Durham based startup focused on hormone replacement therapies, has raised about $5 million from 34 private investors, according to the Raleigh News & Observer. (more…)

Alpharetta, GA - Alimera Sciences, a biopharmaceutical company developing prescription opthalmic products, has filed with the U.S. Securities and Exchange Commission to raise about $75 million in an initial public offering of stock. (more…)

Atlanta, GA–Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals, Inc. to develop and market ADX415, a novel patented, centrally-acting alpha adrenergic receptor agonist, specific to Alpha-2 receptors, for the treatment of hypertension and other potential indications. Under the terms of the agreement, Sciele will have the worldwide marketing rights for ADX415, will pay the product development costs, and will also make regulatory milestone payments and royalty payments to Addrenex on product sales. Sciele and Addrenex expect to begin the Phase II clinical studies in the second half of 2008. (more…)

Durham, NC– CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced it closed a $25 million Series B financing. New investor Care Capital led the round, which included previous investors Pappas Ventures, Domain Associates, Pearl Street Venture Funds and Triathlon Medical Ventures. (more…)